AlzeCure Pharma AB (SE:ALZCUR)

:ALZCUR

ALZCUR

AlzeCure Pharma AB

RESEARCH TOOLSreports

Want to see SE:ALZCUR full AI Analyst Report?

AlzeCure Pharma AB (ALZCUR) Price & Analysis

0 Followers

ALZCUR Stock Chart & Stats

kr2.44

kr0.16(7.05%)

At close: Mar 06 4:00 PM EST

kr2.44

kr0.16(7.05%)

Day’s Range― - ―

52-Week Rangekr1.30 - kr4.95

Previous CloseN/A

Volume72.39K

Average Volume (3M)52.87K

Market Cap

kr160.31M

Enterprise Valuekr129.63M

Total Cash (Recent Filing)kr50.34M

Total Debt (Recent Filing)kr5.12M

Price to Earnings (P/E)―

Beta-0.13

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.45

Shares Outstanding114,914,450

10 Day Avg. Volume28,042

30 Day Avg. Volume52,872

Financial Highlights & Ratios

PEG Ratio-1.94

Price to Book (P/B)6.11

Price to Sales (P/S)0.00

P/FCF Ratio-5.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.4

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage And Balance Sheet FlexibilityModest debt and a low debt-to-equity ratio materially reduce near-term refinancing and interest burden risk. For an R&D biotech, low leverage preserves optionality to pursue licensing deals, collaborations or selective financing without immediate solvency pressure.

Partnering/licensing-focused Business ModelA licensing-first model is capital-efficient for a pre-revenue biotech: it leverages the company's discovery work while shifting late-stage development, commercialization costs and execution risk to partners. This structural route can deliver outsized upside per successful candidate.

CNS/alzheimer's-focused R&D PlatformConcentrated expertise in CNS and Alzheimer’s addresses large unmet medical needs and persistent market demand. A platform approach and multiple early-stage programs raise the probability that at least one candidate can be advanced or out-licensed, providing durable strategic optionality.

Bears Say

No Revenue And Persistent Net LossesAbsence of commercial revenue and recurring net losses mean operations depend on external funding. Over months this constrains strategic flexibility, can force dilutive financing, and raises execution risk if capital markets tighten or partnership timelines slip.

Eroding Equity Base And Negative ROESubstantial equity erosion reduces the balance sheet buffer available for R&D and makes future financings more dilutive or expensive. Persistently negative returns signal that capital deployed is not yet generating value, elevating long-term funding and survival risk.

Consistent Negative Operating And Free Cash FlowRepeated negative operating and free cash flow indicate structural cash burn from R&D activities. This creates ongoing reliance on equity raises or partnerships to fund pipelines, which can delay programs, increase dilution risk, and constrain long-term strategy execution.

ALZCUR FAQ

What was AlzeCure Pharma AB’s price range in the past 12 months?

AlzeCure Pharma AB lowest stock price was kr1.30 and its highest was kr4.95 in the past 12 months.

What is AlzeCure Pharma AB’s market cap?

AlzeCure Pharma AB’s market cap is kr160.31M.

When is AlzeCure Pharma AB’s upcoming earnings report date?

AlzeCure Pharma AB’s upcoming earnings report date is Aug 26, 2026 which is in 93 days.

How were AlzeCure Pharma AB’s earnings last quarter?

AlzeCure Pharma AB released its earnings results on May 05, 2026. The company reported -kr0.189 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.189.

Is AlzeCure Pharma AB overvalued?

According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AlzeCure Pharma AB pay dividends?

AlzeCure Pharma AB does not currently pay dividends.

What is AlzeCure Pharma AB’s EPS estimate?

AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AlzeCure Pharma AB have?

AlzeCure Pharma AB has 114,914,450 shares outstanding.

What happened to AlzeCure Pharma AB’s price movement after its last earnings report?

AlzeCure Pharma AB reported an EPS of -kr0.189 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.06%.

Which hedge fund is a major shareholder of AlzeCure Pharma AB?

Currently, no hedge funds are holding shares in SE:ALZCUR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AlzeCure Pharma AB

AlzeCure Pharma AB (ALZCUR) is a Swedish pharmaceutical company that focuses on developing innovative therapies for neurodegenerative diseases, with a particular emphasis on Alzheimer's disease and pain management. The company operates in the biotechnology sector, leveraging its expertise in neuroscience to advance its pipeline of drug candidates. AlzeCure's core products include a range of proprietary small molecule drugs that target key pathways involved in neurodegeneration.